The prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned development of RG6206, a myostatin inhibitor. The Swiss group revealed the ...

have recently been testing myostatin inhibitors in phase three trials in patients with spinal muscular atrophy, or SMA, a ...

For a number of years it has been suggested that inhibiting myostatin could be a treatment for degenerative muscle diseases such as DMD, although experimental evidence has been conflicting.

A trial found magnetic resonance imaging correlated with physical function tests in patients with Duchenne muscular dystrophy ...

Myostatin inhibitors, designed to promote muscle growth, are being developed for the treatment of muscular dystrophy, among other disorders. Pharmaceutical companies are also examining whether these ...